1. Known to receive hormone therapy orally or intravenously, 2. Hormone therapy is needed due to concomitant disease upon admission, 3. Patients with diabetes are receiving oral medication or insulin therapy, 4. Known contraindications to dexamethasone or other excipients (such as refractory hypertension, epilepsy or delirium and glaucoma), 5. Known active gastrointestinal bleeding in the past 3 months, 6. Known difficulties in correcting hypokalemia, 7. Known secondary bacterial or fungal infections, 8. Known immunosuppressive status (such as chemotherapy / radiotherapy / HIV infection within one month after surgery), 9. The clinician thinks that participating in the trial may cause patient damage (such as severe lymphocyte reduction), 10. The patient may be transferred to a non-participating hospital within 72 hours.

1. Known to receive hormone therapy orally or intravenously, 2. Hormone therapy is needed due to concomitant disease upon admission, 3. Patients with diabetes are receiving oral medication or insulin therapy, 4. Known contraindications to dexamethasone or other excipients (such as refractory hypertension, epilepsy or delirium and glaucoma), 5. Known active gastrointestinal bleeding in the past 3 months, 6. Known difficulties in correcting hypokalemia, 7. Known secondary bacterial or fungal infections, 8. Known immunosuppressive status (such as chemotherapy / radiotherapy / HIV infection within one month after surgery), 9. The clinician thinks that participating in the trial may cause patient damage (such as severe lymphocyte reduction), 10. The patient may be transferred to a non-participating hospital within 72 hours.